검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Targeted CEA CAR-T |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | CEA |
Overview Indication | Advanced Lung Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T) based on scFv 1G9 induced specific and strong antitumor activity in a mouse model of prostate cancer |
MoA Biomarker | PD-1-TREM2 scFv-secreting CAR-T cells resulted in high |
PK/PD Species | Macaque, Mouse, The primary endpoint was safety, secondary endpoints included efficacy, pharmacokinetics and pharmacodynamics. |
PK/PD Animal (cat.) | Mouse, Monkey |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Macaque, Mouse, The primary endpoint was safety, secondary endpoints included efficacy, pharmacokinetics and pharmacodynamics. |
Toxicology Animal (cat.) | Mouse, Monkey |
Toxicology Major finding | Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.. Chimeric antigen receptor (CAR) T cell therapy for solid tumors remains challenging. This phase 1, open-label, dose-escalation and expansion study (ClinicalTrials.gov registration: NCT05396300 ) evaluated the safety and efficacy of PC13, a hypoxia-responsive, … |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Targeted CEA CAR-T |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | CEA |
Overview Indication | Advanced Lung Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T) based on scFv 1G9 induced specific and strong antitumor activity in a mouse model of prostate cancer |
MoA Biomarker | PD-1-TREM2 scFv-secreting CAR-T cells resulted in high |
PK/PD Species | Macaque, Mouse, The primary endpoint was safety, secondary endpoints included efficacy, pharmacokinetics and pharmacodynamics. |
PK/PD Animal (cat.) | Mouse, Monkey |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Macaque, Mouse, The primary endpoint was safety, secondary endpoints included efficacy, pharmacokinetics and pharmacodynamics. |
Toxicology Animal (cat.) | Mouse, Monkey |
Toxicology Major finding | Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.. Chimeric antigen receptor (CAR) T cell therapy for solid tumors remains challenging. This phase 1, open-label, dose-escalation and expansion study (ClinicalTrials.gov registration: NCT05396300 ) evaluated the safety and efficacy of PC13, a hypoxia-responsive, … |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교